Incannex Healthcare (IXHL) Stock Price

Incannex Healthcare Price

NYSE·CLOSED
2.91
​
Market closed

Over the last 19 years Incannex Healthcare grew revenue by 23.8% annually, reaching 86,000.00 USD. For Incannex Healthcare, the net margin of -54,517.4% is down versus -571.5% a few years ago.

Incannex Healthcare stock price

Access this data via the Eulerpool API

Incannex Healthcare business model & stock analysis

Incannex Healthcare Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York. The company went IPO on 2022-03-18. Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The firm is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Frequently asked questions about Incannex Healthcare

7 analysts currently rate the Incannex Healthcare stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Incannex Healthcare to generate revenue of 700,000.00 USD and earnings per share of -1.56 USD.

Converted at the current exchange rate, the Incannex Healthcare share trades at 2.60 EUR (2.91 USD).

The expected revenue of Incannex Healthcare is 700,000.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Incannex Healthcare is -1.80 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Incannex Healthcare is currently -1.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Incannex Healthcare stock.

The price-to-sales ratio (P/S) of Incannex Healthcare is currently 4.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Incannex Healthcare stock.

The Eulerpool Quality Score for Incannex Healthcare is 3/10.

The ISIN of Incannex Healthcare is US45333F2083. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Incannex Healthcare is IXHL. The ticker symbol is used to trade Incannex Healthcare shares on the stock exchange.

Fair ValueTerminal
2.68 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website incannex.com
Currency
USD
Initial public offering
Mar 18, 2022
ISIN
US45333F2083
Market capitalization
3.34 M USDMicro Cap
52-Week Range
PEG
-0.01
P/E ratio
P/Ee 2026
-1.86
P/Ee 2027
-1.99
P/Ee 2028
-1.57
P/Se
4.77
EV/EBIT
0.49
P/B Ratio
0.25
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-350.18 %
Last updated Oct 14, 2026, 11:26 AM

Incannex Healthcare Peer Group